PMID- 32871536
OWN - NLM
STAT- MEDLINE
DCOM- 20210825
LR  - 20210825
IS  - 1618-0631 (Electronic)
IS  - 0344-0338 (Linking)
VI  - 216
IP  - 11
DP  - 2020 Nov
TI  - HER2 immunohistochemistry staining positivity is strongly predictive of tumor 
      response to neoadjuvant chemotherapy in HER2 positive breast cancer.
PG  - 153155
LID - S0344-0338(20)32010-0 [pii]
LID - 10.1016/j.prp.2020.153155 [doi]
AB  - BACKGROUND: The current recommendation is to reflex test HER2 
      immunohistochemistry (IHC) equivocal breast cancer cases with fluorescence in 
      situ hybridization (FISH) analysis. Either IHC 3+ or FISH positive cancers are 
      considered HER2 positive (HER2+) and treated with HER2 targeted therapy. This 
      study examined the predictive value of HER IHC or FISH positivity in tumor 
      response to HER2 targeted therapy. METHODS: Biopsies of 76 HER2+ breast cancer 
      cases were evaluated. All patients were treated with neoadjuvant HER2 targeted 
      therapy and chemotherapy. Tumor response was evaluated on the excisional 
      specimens. Cancers with complete pathologic response (pCR) or MD Anderson 
      residual cancer burden-I (RCB-I) were classified as responders and cancers with 
      RCB-II/III as non-responders. Clinicopathologic parameters were correlated with 
      response. RESULTS: In univariate analysis, small tumor size, low nuclear grade, 
      high Ki67, HER2 IHC 3+, homogenous strong HER2 IHC staining, high HER2/CEP17 
      ratio, and high HER2 copy number were significantly associated with pCR/RCB-I. In 
      multivariate analysis, homogenous strong HER2 IHC staining pattern was 
      significantly associated with pCR/RCB-I. The receiver operating characteristics 
      (ROC) model showed either high HER2/CEP17 ratio or HER2 copy number individually 
      was predictive of tumor response. CONCLUSION: HER2 IHC staining pattern is 
      significantly associated with tumor response to neoadjuvant chemotherapy, 
      reiterating the importance of HER2 IHC evaluation. The ROC model shows either 
      high HER2/CEP17 ratio or high HER2 copy number individually is predictive of 
      tumor response to neoadjuvant HER2 targeted therapy in HER2+ breast cancer.
CI  - Copyright (c) 2020 Elsevier GmbH. All rights reserved.
FAU - Zhao, Jing
AU  - Zhao J
AD  - Department of Pathology, The Affiliated Hospital of Qingdao University, Qingdao, 
      China.
FAU - Krishnamurti, Uma
AU  - Krishnamurti U
AD  - Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA, 
      United States.
FAU - Zhang, Chao
AU  - Zhang C
AD  - Biostatistics and Bioinformatics Shared Resource, Emory University, Atlanta, GA, 
      United States.
FAU - Meisel, Jane
AU  - Meisel J
AD  - Department of Hematology and Medical Oncology, Emory University, Atlanta, GA, 
      United States.
FAU - Wei, Zhimin
AU  - Wei Z
AD  - Department of Pathology, The Affiliated Hospital of Qingdao University, Qingdao, 
      China.
FAU - Suo, Aili
AU  - Suo A
AD  - Department of Oncology, The First Affiliated Hospital of Xi'an Jiaotong 
      University, Xi'an, China.
FAU - Aneja, Ritu
AU  - Aneja R
AD  - Department of Biology, Georgia State University, Atlanta, GA, United States.
FAU - Li, Zaibo
AU  - Li Z
AD  - Department of Pathology, Ohio State University, Columbus, OH, United States.
FAU - Li, Xiaoxian
AU  - Li X
AD  - Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA, 
      United States. Electronic address: xli40@emory.edu.
LA  - eng
PT  - Journal Article
DEP - 20200810
PL  - Germany
TA  - Pathol Res Pract
JT  - Pathology, research and practice
JID - 7806109
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Biomarkers, Tumor)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - K16AIQ8CTM (pertuzumab)
RN  - P188ANX8CK (Trastuzumab)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antibodies, Monoclonal, Humanized/therapeutic use
MH  - Antineoplastic Agents/*therapeutic use
MH  - Biomarkers, Tumor/*analysis
MH  - Breast Neoplasms/*drug therapy/metabolism
MH  - Chemotherapy, Adjuvant/methods
MH  - Female
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Middle Aged
MH  - Molecular Targeted Therapy/methods
MH  - Neoadjuvant Therapy/methods
MH  - Receptor, ErbB-2/*analysis
MH  - Trastuzumab/therapeutic use
MH  - Treatment Outcome
OTO - NOTNLM
OT  - HER2 heterogeneity
OT  - HER2 targeted therapy
OT  - HER2+ breast cancer
OT  - Immunohistochemistry staining pattern
OT  - Neoadjuvant therapy
OT  - Predictive
OT  - Response
EDAT- 2020/09/02 06:00
MHDA- 2021/08/26 06:00
CRDT- 2020/09/02 06:00
PHST- 2020/07/03 00:00 [received]
PHST- 2020/07/30 00:00 [revised]
PHST- 2020/08/01 00:00 [accepted]
PHST- 2020/09/02 06:00 [pubmed]
PHST- 2021/08/26 06:00 [medline]
PHST- 2020/09/02 06:00 [entrez]
AID - S0344-0338(20)32010-0 [pii]
AID - 10.1016/j.prp.2020.153155 [doi]
PST - ppublish
SO  - Pathol Res Pract. 2020 Nov;216(11):153155. doi: 10.1016/j.prp.2020.153155. Epub 
      2020 Aug 10.